Literature DB >> 11044105

Utilization of the bovine papillomavirus type 1 late-stage-specific nucleotide 3605 3' splice site is modulated by a novel exonic bipartite regulator but not by an intronic purine-rich element.

Z M Zheng1, E S Reid, C C Baker.   

Abstract

Bovine papillomavirus type 1 (BPV-1) late gene expression is regulated at both transcriptional and posttranscriptional levels. Maturation of the capsid protein (L1) pre-mRNA requires a switch in 3' splice site utilization. This switch involves activation of the nucleotide (nt) 3605 3' splice site, which is utilized only in fully differentiated keratinocytes during late stages of the virus life cycle. Our previous studies of the mechanisms that regulate BPV-1 alternative splicing identified three cis-acting elements between these two splice sites. Two purine-rich exonic splicing enhancers, SE1 and SE2, are essential for preferential utilization of the nt 3225 3' splice site at early stages of the virus life cycle. Another cis-acting element, exonic splicing suppressor 1 (ESS1), represses use of the nt 3225 3' splice site. In the present study, we investigated the late-stage-specific nt 3605 3' splice site and showed that it has suboptimal features characterized by a nonconsensus branch point sequence and a weak polypyrimidine track with interspersed purines. In vitro and in vivo experiments showed that utilization of the nt 3605 3' splice site was not affected by SE2, which is intronically located with respect to the nt 3605 3' splice site. The intronic location and sequence composition of SE2 are similar to those of the adenovirus IIIa repressor element, which has been shown to inhibit use of a downstream 3' splice site. Further studies demonstrated that the nt 3605 3' splice site is controlled by a novel exonic bipartite element consisting of an AC-rich exonic splicing enhancer (SE4) and an exonic splicing suppressor (ESS2) with a UGGU motif. Functionally, this newly identified bipartite element resembles the bipartite element composed of SE1 and ESS1. SE4 also functions on a heterologous 3' splice site. In contrast, ESS2 functions as an exonic splicing suppressor only in a 3'-splice-site-specific and enhancer-specific manner. Our data indicate that BPV-1 splicing regulation is very complex and is likely to be controlled by multiple splicing factors during keratinocyte differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044105      PMCID: PMC110935          DOI: 10.1128/jvi.74.22.10612-10622.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Mechanisms of alternative pre-mRNA splicing.

Authors:  T Maniatis
Journal:  Science       Date:  1991-01-04       Impact factor: 47.728

2.  PCR-mediated recombination: a general method applied to construct chimeric infectious molecular clones of plasma-derived HIV-1 RNA.

Authors:  G Fang; B Weiser; A Visosky; T Moran; H Burger
Journal:  Nat Med       Date:  1999-02       Impact factor: 53.440

3.  Identification, purification, and biochemical characterization of U2 small nuclear ribonucleoprotein auxiliary factor.

Authors:  P D Zamore; M R Green
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

4.  Functional recognition of the 3' splice site AG by the splicing factor U2AF35.

Authors:  S Wu; C M Romfo; T W Nilsen; M R Green
Journal:  Nature       Date:  1999-12-16       Impact factor: 49.962

5.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

6.  A compensatory base change in human U2 snRNA can suppress a branch site mutation.

Authors:  Y Zhuang; A M Weiner
Journal:  Genes Dev       Date:  1989-10       Impact factor: 11.361

7.  Parameters that affect in vitro splicing of bovine papillomavirus type 1 late pre-mRNAs.

Authors:  Z M Zheng; C C Baker
Journal:  J Virol Methods       Date:  2000-03       Impact factor: 2.014

8.  Optimization of a weak 3' splice site counteracts the function of a bovine papillomavirus type 1 exonic splicing suppressor in vitro and in vivo.

Authors:  Z M Zheng; J Quintero; E S Reid; C Gocke; C C Baker
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

9.  Substrate specificities of SR proteins in constitutive splicing are determined by their RNA recognition motifs and composite pre-mRNA exonic elements.

Authors:  A Mayeda; G R Screaton; S D Chandler; X D Fu; A R Krainer
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

10.  Mammalian pre-mRNA branch site selection by U2 snRNP involves base pairing.

Authors:  J Wu; J L Manley
Journal:  Genes Dev       Date:  1989-10       Impact factor: 11.361

View more
  21 in total

1.  Specific inactivation of inhibitory sequences in the 5' end of the human papillomavirus type 16 L1 open reading frame results in production of high levels of L1 protein in human epithelial cells.

Authors:  Brian Collier; Daniel Oberg; Xiaomin Zhao; Stefan Schwartz
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

Review 2.  Split genes and their expression in Kaposi's sarcoma-associated herpesvirus.

Authors:  Zhi-Ming Zheng
Journal:  Rev Med Virol       Date:  2003 May-Jun       Impact factor: 6.989

Review 3.  Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression.

Authors:  Zhi-Ming Zheng
Journal:  J Biomed Sci       Date:  2004 May-Jun       Impact factor: 8.410

Review 4.  Papillomavirus genome structure, expression, and post-transcriptional regulation.

Authors:  Zhi-Ming Zheng; Carl C Baker
Journal:  Front Biosci       Date:  2006-09-01

5.  Kaposi's sarcoma-associated herpesvirus K8beta is derived from a spliced intermediate of K8 pre-mRNA and antagonizes K8alpha (K-bZIP) to induce p21 and p53 and blocks K8alpha-CDK2 interaction.

Authors:  Koji Yamanegi; Shuang Tang; Zhi-Ming Zheng
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

6.  A splicing enhancer in the E4 coding region of human papillomavirus type 16 is required for early mRNA splicing and polyadenylation as well as inhibition of premature late gene expression.

Authors:  Margaret Rush; Xiaomin Zhao; Stefan Schwartz
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  XPC branch-point sequence mutations disrupt U2 snRNP binding, resulting in abnormal pre-mRNA splicing in xeroderma pigmentosum patients.

Authors:  Sikandar G Khan; Koji Yamanegi; Zhi-Ming Zheng; Jennifer Boyle; Kyoko Imoto; Kyu-Seon Oh; Carl C Baker; Engin Gozukara; Ahmet Metin; Kenneth H Kraemer
Journal:  Hum Mutat       Date:  2010-02       Impact factor: 4.878

8.  Identification of an hnRNP A1-dependent splicing silencer in the human papillomavirus type 16 L1 coding region that prevents premature expression of the late L1 gene.

Authors:  Xiaomin Zhao; Margaret Rush; Stefan Schwartz
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

9.  Control of the papillomavirus early-to-late switch by differentially expressed SRp20.

Authors:  Rong Jia; Xuefeng Liu; Mingfang Tao; Michael Kruhlak; Ming Guo; Craig Meyers; Carl C Baker; Zhi-Ming Zheng
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

10.  Exonic splicing enhancer-dependent selection of the bovine papillomavirus type 1 nucleotide 3225 3' splice site can be rescued in a cell lacking splicing factor ASF/SF2 through activation of the phosphatidylinositol 3-kinase/Akt pathway.

Authors:  Xuefeng Liu; Akila Mayeda; Mingfang Tao; Zhi-Ming Zheng
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.